Literature DB >> 14605877

Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2.

Chung-Dar Yang1, Gan-Nan Chang, David Chao.   

Abstract

The aim of this study was to test the protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2. The PCR-amplified SAG2 fragment (558 bp) digested with the restriction enzyme XhoI was inserted into the XhoI site of plasmid pGEX-6p-1, termed pGexSAG2. The PCR-amplified SAG1 fragment (1,008 bp) digested with restriction enzymes EcoRI and XhoI was cloned into the EcoRI/ XhoI sites of a separate plasmid pGEX-6p-1, termed pGexSAG1. The SAG2 fragment (HindIII/HindIII) excised from pGexSAG2 was inserted into the HindIII site of pGexSAG1 and a chimeric vector constructed, pGexSAG1/2. The fusion proteins GST-SAG1/2, GST-SAG1 and GST-SAG2 were expressed in BL21 Star (DE3) Escherichia coli and purified by GSTrap FF columns. After removing the GST tag, the recombinant proteins rSAG1/2, rSAG1 and rSAG2 were independently collected and injected into different groups of mice to evaluate their protective capability. The highest proliferation of splenocytes stimulated with tachyzoite sonicate antigen (TsoAg) was observed in BALB/c mice which had received two intraperitoneal injections of rSAG1/2. Maximum production of IFN-gamma was also found in the culture supernatants of TsoAg-stimulated splenocytes from rSAG1/2-immunized mice. Finally, 73% (11/15) of mice immunized with rSAG1/2 survived at least 28 days after a lethal challenge of 1 x 10(3) live tachyzoites which killed all non-immunized mice within 10 days. Moderate survival rates were observed in mice immunized with either rSAG1 (60%) or rSAG2 (53%). These results show that the chimeric protein rSAG1/2 can elicit a Th1-associated protection against T. gondii infections in mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605877     DOI: 10.1007/s00436-003-0992-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  24 in total

1.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

2.  Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii.

Authors:  J L Burg; D Perelman; L H Kasper; P L Ware; J C Boothroyd
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Modified protection against Toxoplasma gondii lethal infection and brain cyst formation by vaccination with SAG2 and SRS1.

Authors:  M Mishima; X Xuan; A Shioda; Y Omata; K Fujisaki; H Nagasawa; T Mikami
Journal:  J Vet Med Sci       Date:  2001-04       Impact factor: 1.267

5.  Cloning, expression, and cDNA sequence of surface antigen P22 from Toxoplasma gondii.

Authors:  J B Prince; K L Auer; J Huskinson; S F Parmley; F G Araujo; J S Remington
Journal:  Mol Biochem Parasitol       Date:  1990-11       Impact factor: 1.759

6.  Live and killed vaccines against toxoplasmosis in mice.

Authors:  H Waldeland; J K Frenkel
Journal:  J Parasitol       Date:  1983-02       Impact factor: 1.276

7.  CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice.

Authors:  S J Parker; C W Roberts; J Alexander
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

8.  Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii.

Authors:  E Petersen; H V Nielsen; L Christiansen; J Spenter
Journal:  Vaccine       Date:  1998-08       Impact factor: 3.641

9.  Toxoplasmosis: the first commercial vaccine.

Authors:  D Buxton
Journal:  Parasitol Today       Date:  1993-09

10.  Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii-infected cells.

Authors:  C S Subauste; A H Koniaris; J S Remington
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

View more
  11 in total

1.  Effect of rSAG-1(P30) immunisation on the circulating and tissue parasites in guinea pigs as determined by quantitative PCR.

Authors:  Pierre Flori; Laëtitia Tardy; Alain Jacquet; Bahrie Bellete; Jamal Hafid; Hélène Raberin; Roger Tran Manh Sung
Journal:  Parasitol Res       Date:  2006-01-17       Impact factor: 2.289

2.  A new MIC1-MAG1 recombinant chimeric antigen can be used instead of the Toxoplasma gondii lysate antigen in serodiagnosis of human toxoplasmosis.

Authors:  Lucyna Holec-Gąsior; Bartłomiej Ferra; Dorota Drapała; Dariusz Lautenbach; Józef Kur
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

3.  Immunogenic characterization of the chimeric surface antigen 1 and 2 (SAG1/2) of Toxoplasma gondii expressed in the yeast Pichia pastoris.

Authors:  Yee Ling Lau; Girija Thiruvengadam; Wei Wei Lee; Mun Yik Fong
Journal:  Parasitol Res       Date:  2011-04-01       Impact factor: 2.289

4.  Induction of Protective Immunity against Toxoplasmosis in BALB/c Mice Vaccinated with Toxoplasma gondii Rhoptry-1.

Authors:  Parthasarathy Sonaimuthu; Xiao T Ching; Mun Y Fong; Ramaswamy Kalyanasundaram; Yee L Lau
Journal:  Front Microbiol       Date:  2016-05-27       Impact factor: 5.640

5.  Protective immunity against toxoplasmosis in mice induced by single-dose immunization with rSAG1/2 protein released from poly(lactide-co-glycolide) microparticles.

Authors:  Shu-Chun Chuang; Yao-Chi Chung; Chung-Da Yang
Journal:  Parasite       Date:  2017-02-01       Impact factor: 3.000

Review 6.  Importance of serological cross-reactivity among Toxoplasma gondii, Hammondia spp., Neospora spp., Sarcocystis spp. and Besnoitia besnoiti.

Authors:  Luís F P Gondim; José R Mineo; Gereon Schares
Journal:  Parasitology       Date:  2017-02-28       Impact factor: 3.234

7.  Recombinant TgHSP70 Immunization Protects against Toxoplasma gondii Brain Cyst Formation by Enhancing Inducible Nitric Oxide Expression.

Authors:  Paulo Czarnewski; Ester C B Araújo; Mário C Oliveira; Tiago W P Mineo; Neide M Silva
Journal:  Front Cell Infect Microbiol       Date:  2017-04-25       Impact factor: 5.293

8.  Toxoplasma gondii ADSL Knockout Provides Excellent Immune Protection against a Variety of Strains.

Authors:  Luyao Wang; Ding Tang; Chenghang Yang; Jing Yang; Rui Fang
Journal:  Vaccines (Basel)       Date:  2020-01-06

9.  Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.

Authors:  Shu-Chun Chuang; Jing-Chun Ko; Chaio-Ping Chen; Jia-Tze Du; Chung-Da Yang
Journal:  Parasit Vectors       Date:  2013-02-11       Impact factor: 3.876

10.  Pleurocidin Peptide Enhances Grouper Anti-Vibrio harveyi Immunity Elicited by Poly(lactide-co-glycolide)-Encapsulated Recombinant Glyceraldehyde-3-phosphate Dehydrogenase.

Authors:  Shu-Chun Chuang; Wan-Ling Huang; Sau-Wei Kau; Yun-Pei Yang; Chung-Da Yang
Journal:  Vaccines (Basel)       Date:  2014-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.